While injectable forms of semaglutide are available around the globe, the oral form, available in India, is helping doctors see results in diabetes control with the added benefit of weight loss
visual, hearing, or cognitive impairment
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet
Quick Answer for B2B Buyers What is this product
This article provides a detailed comparison of semaglutide and tirzepatide, including how they work, clinical outcomes, dosing considerations, and access factors, to help patients and healthcare professionals determine which therapy best aligns with specific health goals and preferences